See more : Mechel PAO (MTL) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai Hile Bio-Technology Co., Ltd. (603718.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai Hile Bio-Technology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Vaisala Oyj (0GEG.L) Income Statement Analysis – Financial Results
- Model Performance Acquisition Corp. (MPACR) Income Statement Analysis – Financial Results
- GenSight Biologics S.A. (SIGHT.PA) Income Statement Analysis – Financial Results
- Icelandair Group hf. (ICEAIR.IC) Income Statement Analysis – Financial Results
- Strata Investment Holdings Plc (SRT.AX) Income Statement Analysis – Financial Results
Shanghai Hile Bio-Technology Co., Ltd. (603718.SS)
About Shanghai Hile Bio-Technology Co., Ltd.
Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 240.72M | 299.99M | 347.29M | 259.13M | 277.99M | 254.57M | 303.65M | 343.34M | 316.58M | 285.27M | 318.79M | 310.84M | 260.13M |
| Cost of Revenue | 117.00M | 123.09M | 153.62M | 137.76M | 148.71M | 112.42M | 69.22M | 84.03M | 73.53M | 61.80M | 71.07M | 69.07M | 61.51M |
| Gross Profit | 123.72M | 176.90M | 193.67M | 121.37M | 129.29M | 142.15M | 234.43M | 259.31M | 243.05M | 223.47M | 247.72M | 241.77M | 198.61M |
| Gross Profit Ratio | 51.39% | 58.97% | 55.77% | 46.84% | 46.51% | 55.84% | 77.20% | 75.53% | 76.77% | 78.34% | 77.71% | 77.78% | 76.35% |
| Research & Development | 24.97M | 29.94M | 28.64M | 29.53M | 29.64M | 27.28M | 20.16M | 20.71M | 19.68M | 17.86M | 14.93M | 14.33M | 0.00 |
| General & Administrative | 8.72M | 20.12M | 10.86M | 22.48M | 19.13M | 20.59M | 10.18M | 11.07M | 8.82M | 47.69M | 39.43M | 37.35M | 32.66M |
| Selling & Marketing | 40.83M | 57.74M | 79.47M | 51.79M | 59.30M | 70.46M | 97.17M | 116.15M | 91.01M | 76.33M | 79.03M | 78.92M | 52.09M |
| SG&A | 49.55M | 77.86M | 90.33M | 74.27M | 78.43M | 91.05M | 107.35M | 127.22M | 99.83M | 124.02M | 118.46M | 116.27M | 84.75M |
| Other Expenses | -6.54M | -5.84M | 36.95M | 28.22M | 23.77M | -23.41M | 2.29M | 4.17M | -1.24M | 12.31M | 7.39M | 5.22M | 9.56M |
| Operating Expenses | 65.25M | 101.96M | 155.92M | 132.02M | 131.84M | 137.82M | 140.57M | 196.15M | 145.48M | 124.96M | 119.82M | 117.58M | 85.95M |
| Cost & Expenses | 185.55M | 225.05M | 309.54M | 269.78M | 280.55M | 250.24M | 209.79M | 280.18M | 219.01M | 186.77M | 190.89M | 186.65M | 147.47M |
| Interest Income | 2.64M | 2.15M | 174.91K | 145.57K | 66.85K | 527.46K | 2.69M | 4.71M | 8.85M | 6.75M | 6.63M | 3.28M | 0.00 |
| Interest Expense | 5.39M | 10.31M | 12.38M | 17.69M | 18.17M | 14.90M | 11.80M | 5.95M | 94.25K | 6.14M | 663.33K | 460.83K | 0.00 |
| Depreciation & Amortization | 40.87M | 49.65M | 61.46M | 67.68M | 67.61M | 61.71M | 58.13M | 51.42M | 29.82M | 28.20M | 24.63M | 21.88M | 10.56M |
| EBITDA | 101.12M | 183.28M | 120.47M | 59.72M | 93.15M | 70.87M | 116.71M | 134.31M | 138.32M | 126.71M | 164.63M | 154.21M | 123.22M |
| EBITDA Ratio | 42.01% | 66.65% | 35.46% | 27.28% | 31.38% | 27.18% | 56.69% | 37.30% | 43.55% | 44.40% | 52.20% | 49.72% | 47.25% |
| Operating Income | 55.17M | 152.57M | 57.24M | 12.47M | 29.59M | 22.18M | 104.84M | 73.11M | 109.61M | 104.73M | 132.19M | 126.84M | 116.73M |
| Operating Income Ratio | 22.92% | 50.86% | 16.48% | 4.81% | 10.64% | 8.71% | 34.53% | 21.29% | 34.62% | 36.71% | 41.47% | 40.80% | 44.87% |
| Total Other Income/Expenses | 851.85K | -21.35M | -102.34K | -35.81M | -22.76M | -23.41M | 2.29M | 4.17M | -1.27M | 12.28M | 7.15M | 7.67M | 9.56M |
| Income Before Tax | 56.02M | 131.22M | 57.14M | -23.34M | 6.83M | -1.23M | 107.12M | 76.89M | 108.34M | 117.01M | 139.34M | 131.86M | 126.29M |
| Income Before Tax Ratio | 23.27% | 43.74% | 16.45% | -9.01% | 2.46% | -0.48% | 35.28% | 22.40% | 34.22% | 41.02% | 43.71% | 42.42% | 48.55% |
| Income Tax Expense | 6.01M | 20.53M | 11.47M | 8.81M | 33.24M | 12.48M | 11.83M | 6.85M | 17.01M | 17.17M | 20.92M | 19.32M | 19.01M |
| Net Income | 62.87M | 121.61M | 53.86M | -32.15M | -26.41M | 21.30M | 113.74M | 85.54M | 95.40M | 101.22M | 118.79M | 112.55M | 107.27M |
| Net Income Ratio | 26.12% | 40.54% | 15.51% | -12.41% | -9.50% | 8.37% | 37.46% | 24.91% | 30.14% | 35.48% | 37.26% | 36.21% | 41.24% |
| EPS | 0.10 | 0.19 | 0.08 | -0.05 | -0.04 | 0.03 | 0.18 | 0.13 | 0.17 | 0.21 | 0.23 | 0.22 | 0.20 |
| EPS Diluted | 0.10 | 0.19 | 0.08 | -0.05 | -0.04 | 0.03 | 0.18 | 0.13 | 0.17 | 0.21 | 0.23 | 0.22 | 0.20 |
| Weighted Avg Shares Out | 628.70M | 644.00M | 644.00M | 644.00M | 644.00M | 709.94M | 631.89M | 644.00M | 561.19M | 485.01M | 483.00M | 483.00M | 536.37M |
| Weighted Avg Shares Out (Dil) | 628.70M | 644.00M | 644.00M | 644.00M | 644.00M | 709.94M | 631.89M | 657.97M | 561.19M | 485.02M | 505.96M | 507.56M | 536.37M |
Source: https://incomestatements.info
Category: Stock Reports